ArticleDrug safety2022
Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
Article in Drug safety, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Machine learning-assisted mRNA vaccine pharmacovigilance: a systematic review of multi-source real-world data.BMC medical informatics and decision making · 2026Pooled it
- The Impact and Role of Artificial Intelligence (AI) in Healthcare: Systematic Review.Current topics in medicinal chemistry · 2025Pooled it
- Human Dignity and Artificial Intelligence in Healthcare: A Basis for a Catholic Ethics on AI.Journal of religion and health · 2026Article
- Governing AI for Pharmacovigilance in Low-Income Countries: Systems Perspective.Journal of medical Internet research · 2026Article
- Computational Prediction of the Severity of Adverse Drug Reactions Caused by Drug-Drug Interactions.Pharmaceuticals (Basel, Switzerland) · 2026Article
- AI for Causality Assessment in Pharmacovigilance: Protocol for a Scoping Review.JMIR research protocols · 2026Article
- Review
- Accelerated drug development using a digital formulator and a self-driving tableting data factory.Nature communications · 2026Article
- Building the next frontier: Artificial intelligence in 3D-printed medicines.Biomaterials translational · 2026Review
- Adoption of artificial intelligence in the HRM function within the South African telecommunication sector: a quantitative analysis using structural equation modelling.Frontiers in artificial intelligence · 2026Article
- Article
- Artificial intelligence in healthcare: applications, challenges, and future directions. A narrative review informed by international, multidisciplinary expertise.Frontiers in digital health · 2025Review
- A national pharmacovigilance centre perspective on pandemic preparedness -Frontiers in drug safety and regulation · 2025Article
- Pharmacovigilance - Technological Advancements, Recent Developments and Innovations.Current drug safety · 2025Review
- Parents' understanding and attitudes toward the application of AI in pediatric healthcare: a cross-sectional survey study.Frontiers in public health · 2025Observational
- Review
- Data Safety Monitoring Boards: Overview of Structure and Role in Spinal Cord Injury Studies.Topics in spinal cord injury rehabilitation · 2024Review
- Artificial intelligence integration in the drug lifecycle and in regulatory science: policy implications, challenges and opportunities.Frontiers in pharmacology · 2024Article
- A comprehensive review of artificial intelligence for pharmacology research.Frontiers in genetics · 2024Review
- BERT based natural language processing for triage of adverse drug reaction reports shows close to human-level performance.PLOS digital health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdverse drug reaction reports are usually manually assessed by pharmacovigilance experts to detect safety signals associated with drugs. With the recent extension of reporting to patients and the emergence of mass media-related sanitary crises, adverse drug reaction reports currently frequently overwhelm pharmacovigilance networks. Artificial intelligence could help support the work of pharmacovigilance experts during such crises, by automatically coding reports, allowing them to prioritise or accelerate their manual assessment. After a previous study showing first results, we developed and compared state-of-the-art machine learning models using a larger nationwide dataset, aiming to automatically pre-code patients' adverse drug reaction reports.
objectivesWe aimed to determine the best artificial intelligence model identifying adverse drug reactions and assessing seriousness in patients reports from the French national pharmacovigilance web portal.
methodsReports coded by 27 Pharmacovigilance Centres between March 2017 and December 2020 were selected (n = 11,633). For each report, the Portable Document Format form containing free-text information filled by the patient, and the corresponding encodings of adverse event symptoms (in Medical Dictionary for Regulatory Activities Preferred Terms) and seriousness were obtained. This encoding by experts was used as the reference to train and evaluate models, which contained input data processing and machine-learning natural language processing to learn and predict encodings. We developed and compared different approaches for data processing and classifiers. Performance was evaluated using receiver operating characteristic area under the curve (AUC), F-measure, sensitivity, specificity and positive predictive value. We used data from 26 Pharmacovigilance Centres for training and internal validation. External validation was performed using data from the remaining Pharmacovigilance Centres during the same period.
resultsInternal validation: for adverse drug reaction identification, Term Frequency-Inverse Document Frequency (TF-IDF) + Light Gradient Boosted Machine (LGBM) achieved an AUC of 0.97 and an F-measure of 0.80. The Cross-lingual Language Model (XLM) [transformer] obtained an AUC of 0.97 and an F-measure of 0.78. For seriousness assessment, FastText + LGBM achieved an AUC of 0.85 and an F-measure of 0.63. CamemBERT (transformer) + Light Gradient Boosted Machine obtained an AUC of 0.84 and an F-measure of 0.63. External validation for both adverse drug reaction identification and seriousness assessment tasks yielded consistent and robust results.
conclusionsOur artificial intelligence models showed promising performance to automatically code patient adverse drug reaction reports, with very similar results across approaches. Our system has been deployed by national health authorities in France since January 2021 to facilitate pharmacovigilance of COVID-19 vaccines. Further studies will be needed to validate the performance of the tool in real-life settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.